The Latest Cardiac and Vascular News
— Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis — –– Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular […]
Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of FARXIGA in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64 million people August 27, 2022 10:36 AM Eastern […]
~30% relative risk reduction seen in symptomatic ischemic strokes in three milvexian arms compared to placebo; dose response not observed for primary study objective No fatal bleeding and no increase in symptomatic intracranial hemorrhage observed in patients treated with milvexian, even with all patients receiving 21 days of background dual […]
PHILADELPHIA, Aug. 25, 2022 (GLOBE NEWSWIRE) — ŌNŌCOR LLC announced the use of the ŌNŌ endovascular retrieval system to remove a large central-line-associated thrombus from the right atrium in a teenage patient. The team at Children’s Hospital Los Angeles (CHLA, @ChildrensLA), led by Dr. Darren Berman, Director of Congenital Interventional Catheterization with CHLA’s Heart Institute, […]
— Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses — — Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congress 2022 in Barcelona — DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 26, 2022 (GLOBE NEWSWIRE) — Amarin […]
Treatment with ninerafaxstat significantly improved cardiac energetics, steatosis and left ventricular (LV) diastolic function in patients with type-2 diabetes mellitus (T2DM) and obesity BOSTON, Mass., Aug. 26, 2022 (GLOBE NEWSWIRE) — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced positive […]
ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD) by the American College of Cardiology (ACC) task force on expert […]
MADRID–(BUSINESS WIRE)–The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack. The polypill reduces mortality from cardiovascular causes in this population by 33%. This is […]
-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as well as improvements in liver fat and glycemic control- -Positive data support the advancement into a Phase 3 trial in SHTG- SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) — 89bio, […]
Kaiser Permanente study showed patients in home-based cardiac rehabilitation had fewer hospitalizations than those in center-based cardiac rehabilitation PASADENA, Calif., Aug. 25, 2022 /PRNewswire/ — Patients who participated in in-home cardiac rehabilitation had fewer hospitalizations over 12 months than patients who participated in center-based cardiac rehabilitation, according to a Kaiser Permanente study published August […]
